Industry Odisha Bureau, April 27: Indian drugmaker Sun Pharmaceutical Industries Ltd (Sun Pharma) is all set to purchase US-based Organon & Co in an all-cash deal valued at $11.75 billion.
Media reports added that Sun Pharma will buy “all outstanding shares for $14 per share in cash (approximately $3.99 billion in total equity value)”.
While Sun Pharma Managing Director Kirti Ganorkar told media, “The combined revenue pool could be $12.4 billion with an operating income of $3.7 billion”, the firm’s Executive Chairman Dilip Shanghvi in his media reactions, said, “Organon’s portfolio, capabilities and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform,”
Reports added that the acquisition process is aimed to be “finalised by early 2027”.
Notably, “Organon & Co. is a global healthcare company, spun off from Merck in 2021, focusing on women’s health, biosimilars, and established brands. Headquartered in New Jersey, it boasts a portfolio of over 70 medicines, including contraception and fertility treatments. Apart from the United States of America (USA), the company has a commercial presence globally chiefly in Canada, China and Europe”.
